Abstract
A course of intravesical mitomycin C, consisting of 8 weekly doses of 30 or 40 mg., was evaluated in 16 patients with superficial bladder cancer (stages O and A). Cystoscopically documented tumor was destroyed completely in 11 patients (69 per cent), while 3 patients exhibited partial tumor regression. Two patients had only multifocal, grade 3 carcinoma in situ and both had a complete response with negative biopsies and cytology at the 12-week evaluation. Toxicity was minimal. Further data, including longer followup, are needed to define the potentially promising role of this agent in the over-all management of superficial bladder cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 646-648 |
| Number of pages | 3 |
| Journal | Journal of Urology |
| Volume | 125 |
| Issue number | 5 |
| State | Published - Aug 17 1981 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Urology
Cite this
The effect of mitomycin C on superficial bladder cancer. / Soloway, M. S.; Murphy, W. M.; DeFuria, M. D.; Crooke, S.; Finebaum, P.
In: Journal of Urology, Vol. 125, No. 5, 17.08.1981, p. 646-648.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The effect of mitomycin C on superficial bladder cancer
AU - Soloway, M. S.
AU - Murphy, W. M.
AU - DeFuria, M. D.
AU - Crooke, S.
AU - Finebaum, P.
PY - 1981/8/17
Y1 - 1981/8/17
N2 - A course of intravesical mitomycin C, consisting of 8 weekly doses of 30 or 40 mg., was evaluated in 16 patients with superficial bladder cancer (stages O and A). Cystoscopically documented tumor was destroyed completely in 11 patients (69 per cent), while 3 patients exhibited partial tumor regression. Two patients had only multifocal, grade 3 carcinoma in situ and both had a complete response with negative biopsies and cytology at the 12-week evaluation. Toxicity was minimal. Further data, including longer followup, are needed to define the potentially promising role of this agent in the over-all management of superficial bladder cancer.
AB - A course of intravesical mitomycin C, consisting of 8 weekly doses of 30 or 40 mg., was evaluated in 16 patients with superficial bladder cancer (stages O and A). Cystoscopically documented tumor was destroyed completely in 11 patients (69 per cent), while 3 patients exhibited partial tumor regression. Two patients had only multifocal, grade 3 carcinoma in situ and both had a complete response with negative biopsies and cytology at the 12-week evaluation. Toxicity was minimal. Further data, including longer followup, are needed to define the potentially promising role of this agent in the over-all management of superficial bladder cancer.
UR - http://www.scopus.com/inward/record.url?scp=0019432928&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019432928&partnerID=8YFLogxK
M3 - Article
C2 - 6785454
AN - SCOPUS:0019432928
VL - 125
SP - 646
EP - 648
JO - Journal of Urology
JF - Journal of Urology
SN - 0022-5347
IS - 5
ER -